Evidence map›Paper›PMID 36569302›Full record

ArticleFrontiers in pharmacology2022

Editorial: Emerging talents in Frontiers in Pharmacology: Drug metabolism and transport 2022.

Terry D Hinds, Massimo Valoti, Yurong Lai, Thomas P C Dorlo, Yan Li

Abstract readEditorial
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Terry D HindsDepartment of Pharmacology and Nutritional Sciences, Barnstable Brown Diabetes Center, Markey Cancer Center, University of Kentucky, Lexington, KY, United States.
Massimo ValotiDepartment of Life Sciences, University of Siena, Siena, Italy.
Yurong LaiDepartment of Drug Metabolism, Gilead Sciences Inc., Foster City, CA, United States.
Thomas P C DorloDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Yan LiSchool of Science, Auckland University of Technology, Auckland, New Zealand.

Funding

Novel Liver Signaling Pathways Controlling AdiposityR01DK121797 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI HINDS, TERRY D · 2020 to 2024
$2.2M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

glucuronyl enzymesmembrane transportersP450 enzymespharmacodynamicspharmacoepigeneticspharmacokineticspharmacometrics

Identifiers

PMID36569302
PMCPMC9771452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.